Sleep attacks in patients taking dopamine agonists: review.
نویسندگان
چکیده
OBJECTIVES To assess the evidence for the existence and prevalence of sleep attacks in patients taking dopamine agonists for Parkinson's disease, the type of drugs implicated, and strategies for prevention and treatment. DESIGN Review of publications between July 1999 and May 2001 in which sleep attacks or narcoleptic-like attacks were discussed in patients with Parkinson's disease. RESULTS 124 patients with sleep events were found in 20 publications. Overall, 6.6% of patients taking dopamine agonists who attended movement disorder centres had sleep events. Men were over-represented. Sleep events occurred at both high and low doses of the drugs, with different durations of treatment (0-20 years), and with or without preceding signs of tiredness. Sleep attacks are a class effect, having been found in patients taking the following dopamine agonists: levodopa (monotherapy in 8 patients), ergot agonists (apomorphine in 2 patients, bromocriptine in 13, cabergoline in 1, lisuride or piribedil in 23, pergolide in 5,) and non-ergot agonists (pramipexole in 32, ropinirole in 38). Reports suggest two distinct types of events: those of sudden onset without warning and those of slow onset with prodrome drowsiness. CONCLUSION Insufficient data are available to provide effective guidelines for prevention and treatment of sleep events in patients taking dopamine agonists for Parkinson's disease. Prospective population based studies are needed to provide this information.
منابع مشابه
Piribedil: sleep attacks, also in patients without Parkinson's disease.
Piribedil is a dopamine agonist used in Parkinson's disease and a variety of other clinical situations although its efficacy has not been demonstrated. A study based on the French national pharmacovigilance database identified and analysed 7 reports of sleep attacks attributed to piribedil in patients without Parkinson's disease. The case reports are detailed and indicate that piribedil has a d...
متن کاملIncreased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials.
BACKGROUND Recent case reports and letters have alerted practitioners to the risk of sleep attacks, usually preceded by somnolence, in patients with Parkinson's disease treated with pramipexole and ropinirole. OBJECTIVE To quantify the risk of somnolence with the new dopamine agonists pramipexole and ropinirole in patients with Parkinson's disease. METHODS We searched MEDLINE, EMBASE, Inter...
متن کاملSleep Disorders and Daytime Sleepiness Are Frequent Findings in Patients with Parkinson Disease (pd).2-6 the Underlying Causes Are Still
SLEEP DISORDERS AND DAYTIME SLEEPINESS ARE FREQUENT FINDINGS IN PATIENTS WITH PARKINSON DISEASE (PD).2-6 THE UNDERLYING CAUSES ARE STILL controversial. In 1999, “sleep attacks” (termed sudden onset of sleep [SOS] in this paper) were described in PD patients taking the nonergoline dopamine-receptor agonists pramipexole and ropinirole.7 SOS is defined by abrupt episodes of unplanned sleep during ...
متن کاملClinical practice regarding dopamine-agonist use and driving in Parkinson's disease.
BACKGROUND Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive. The objective was to assess neurologists' actual clinical practice concerning driving advice they give to PD patients starting a DA. METHODS An online survey was created consisting of 4 items regarding demogr...
متن کاملDopaminergic modulation of behavioral states in mesopontine tegmentum: a reverse microdialysis study in freely moving cats.
STUDY OBJECTIVES We investigated the role of dopamine (DA) in behavioral state control and, in particular, paradoxical (or rapid eye movement) sleep (PS) generation in mesopontine structures. DESIGN Reverse microdialysis and polygraphic recordings in freely moving cats were used to assess the effects on sleep-wake states of applied DA and monoaminergic agonists and antagonists. SETTINGS NA....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- BMJ
دوره 324 7352 شماره
صفحات -
تاریخ انتشار 2002